Isatuximab: This medication is used in the treatment of multiple myeloma, a type of blood cancer. It works by targeting and attaching to a specific protein on the surface of cancer cells, helping the immune system to identify and destroy these cells. In this trial, isatuximab is being tested in two forms of administration: subcutaneous (under the skin) and intravenous (into a vein).

Pomalidomide: This is a medication that helps to slow down or stop the growth of cancer cells. It is used in combination with other drugs to treat multiple myeloma, especially in patients who have not responded to other treatments. Pomalidomide works by affecting the immune system and has anti-cancer properties.

Dexamethasone: This is a type of steroid medication that is used to reduce inflammation and suppress the immune system. In the context of multiple myeloma, dexamethasone is used to help enhance the effects of other cancer treatments and manage symptoms associated with the disease.

Plasma Cell Myeloma Recurrent – Plasma cell myeloma, also known as multiple myeloma, is a type of cancer that affects plasma cells, which are a type of white blood cell found in the bone marrow. In recurrent cases, the disease returns after a period of improvement or remission. It typically progresses by causing an overproduction of abnormal plasma cells, which can crowd out healthy blood cells and lead to bone damage, kidney problems, and weakened immune function. Symptoms may include bone pain, fatigue, frequent infections, and anemia. The disease can vary in its rate of progression, with some individuals experiencing slow development while others may have a more aggressive form.